메뉴 건너뛰기




Volumn 17, Issue 1, 2011, Pages

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: A consensus definition

Author keywords

Bleed; Bypassing agents; Haemophilia; Inhibitors; Non responsiveness

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

EID: 79951916913     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02377.x     Document Type: Article
Times cited : (23)

References (45)
  • 1
    • 33750988816 scopus 로고    scopus 로고
    • Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference
    • Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12(Suppl 6): 1-7.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL 6 , pp. 1-7
    • Berntorp, E.1    Shapiro, A.2    Astermark, J.3
  • 2
    • 33751040152 scopus 로고    scopus 로고
    • Inhibitor treatment in haemophilias A and B: inhibitor diagnosis
    • DiMichele DM. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. Haemophilia 2006; 12(Suppl 6): 37-41.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL 6 , pp. 37-41
    • DiMichele, D.M.1
  • 3
    • 0038383605 scopus 로고    scopus 로고
    • The epidemiology of inhibitors in haemophilia A: a systematic review
    • Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
    • (2003) Haemophilia , vol.9 , pp. 418-435
    • Wight, J.1    Paisley, S.2
  • 4
    • 33646140127 scopus 로고    scopus 로고
    • Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia
    • Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12(Suppl 3): 52-60.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL 3 , pp. 52-60
    • Astermark, J.1
  • 5
    • 9144271883 scopus 로고    scopus 로고
    • The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99
    • Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
    • (2004) J Thromb Haemost , vol.2 , pp. 1047-1054
    • Darby, S.C.1    Keeling, D.M.2    Spooner, R.J.3
  • 6
    • 33751017726 scopus 로고    scopus 로고
    • The epidemiology of factor VIII inhibitors
    • Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006; 12(Suppl 6): 23-8.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL 6 , pp. 23-28
    • Hay, C.R.1
  • 7
    • 0031057651 scopus 로고    scopus 로고
    • HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party
    • Hay CR, Ollier W, Pepper L et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-7.
    • (1997) Thromb Haemost , vol.77 , pp. 234-237
    • Hay, C.R.1    Ollier, W.2    Pepper, L.3
  • 8
    • 33845239946 scopus 로고    scopus 로고
    • Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
    • Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
    • (2006) Blood , vol.108 , pp. 3739-3745
    • Astermark, J.1    Oldenburg, J.2    Carlson, J.3
  • 9
    • 33645751563 scopus 로고    scopus 로고
    • Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
    • Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
    • (2006) Blood , vol.107 , pp. 3167-3172
    • Astermark, J.1    Oldenburg, J.2    Pavlova, A.3    Berntorp, E.4    Lefvert, A.K.5
  • 10
    • 33846420672 scopus 로고    scopus 로고
    • Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
    • Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
    • (2007) J Thromb Haemost , vol.5 , pp. 263-265
    • Astermark, J.1    Wang, X.2    Oldenburg, J.3    Berntorp, E.4    Lefvert, A.K.5
  • 11
    • 64749096663 scopus 로고    scopus 로고
    • Inhibitors of factor VIII in black patients with hemophilia
    • Viel KR, Ameri A, Abshire TC et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
    • (2009) N Engl J Med , vol.360 , pp. 1618-1627
    • Viel, K.R.1    Ameri, A.2    Abshire, T.C.3
  • 12
    • 34249690732 scopus 로고    scopus 로고
    • Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
    • Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
    • (2007) Blood , vol.109 , pp. 4648-4654
    • Gouw, S.C.1    van der Bom, J.G.2    Marijke van den Berg, H.3
  • 13
    • 30344434999 scopus 로고    scopus 로고
    • Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A
    • Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
    • (2006) Blood , vol.107 , pp. 46-51
    • Goudemand, J.1    Rothschild, C.2    Demiguel, V.3
  • 14
    • 33751010515 scopus 로고    scopus 로고
    • Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
    • Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12(Suppl 6): 102-6.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL 6 , pp. 102-106
    • Ettingshausen, C.E.1    Kreuz, W.2
  • 15
    • 11044235586 scopus 로고    scopus 로고
    • Inhibitors in haemophilia: clinical aspects
    • Dimichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004; 10(Suppl 4): 140-5.
    • (2004) Haemophilia , vol.10 , Issue.SUPPL 4 , pp. 140-145
    • Dimichele, D.1    Rivard, G.2    Hay, C.3    Antunes, S.4
  • 16
    • 33751014883 scopus 로고    scopus 로고
    • Basic aspects of bypassing agents
    • Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12(Suppl 6): 48-52.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL 6 , pp. 48-52
    • Negrier, C.1    Dargaud, Y.2    Bordet, J.C.3
  • 17
    • 12144290833 scopus 로고    scopus 로고
    • Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
    • Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467-73.
    • (2004) Blood , vol.103 , pp. 2467-2473
    • Soucie, J.M.1    Cianfrini, C.2    Janco, R.L.3
  • 18
    • 33645963126 scopus 로고    scopus 로고
    • Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors
    • Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
    • (2006) Haemophilia , vol.12 , pp. 154-162
    • Scalone, L.1    Mantovani, L.G.2    Mannucci, P.M.3    Gringeri, A.4
  • 19
    • 40449108264 scopus 로고    scopus 로고
    • Some recent developments regarding arthropathy and inhibitors in haemophilia
    • Rodriguez-Merchan EC. Some recent developments regarding arthropathy and inhibitors in haemophilia. Haemophilia 2008; 14: 242-7.
    • (2008) Haemophilia , vol.14 , pp. 242-247
    • Rodriguez-Merchan, E.C.1
  • 20
    • 17544400786 scopus 로고    scopus 로고
    • Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study
    • Shapiro AD, Donfield SM, Lynn HS et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: E105.
    • (2001) Pediatrics , vol.108
    • Shapiro, A.D.1    Donfield, S.M.2    Lynn, H.S.3
  • 21
    • 0141482007 scopus 로고    scopus 로고
    • Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
    • Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
    • (2003) Blood , vol.102 , pp. 2358-2363
    • Gringeri, A.1    Mantovani, L.G.2    Scalone, L.3    Mannucci, P.M.4
  • 22
    • 34248594449 scopus 로고    scopus 로고
    • A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
    • Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
    • (2007) Haemophilia , vol.13 , pp. 256-263
    • Teitel, J.1    Berntorp, E.2    Collins, P.3
  • 24
    • 0030837755 scopus 로고    scopus 로고
    • Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity
    • Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
    • (1997) Thromb Haemost , vol.77 , pp. 1113-1119
    • Negrier, C.1    Goudemand, J.2    Sultan, Y.3    Bertrand, M.4    Rothschild, C.5    Lauroua, P.6
  • 25
    • 20144389671 scopus 로고    scopus 로고
    • Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
    • Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
    • (2005) Haemophilia , vol.11 , pp. 100-106
    • Parameswaran, R.1    Shapiro, A.D.2    Gill, J.C.3    Kessler, C.M.4
  • 26
    • 35148857177 scopus 로고    scopus 로고
    • Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
    • Tjonnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag 2007; 3: 527-31.
    • (2007) Vasc Health Risk Manag , vol.3 , pp. 527-531
    • Tjonnfjord, G.E.1    Holme, P.A.2
  • 27
    • 63049090494 scopus 로고    scopus 로고
    • Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors
    • Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
    • (2009) Haemophilia , vol.15 , pp. 3-10
    • Berntorp, E.1
  • 28
    • 33750342991 scopus 로고    scopus 로고
    • A retrospective postlicensure survey of FEIBA efficacy and safety
    • Dimichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
    • (2006) Haemophilia , vol.12 , pp. 352-362
    • Dimichele, D.1    Negrier, C.2
  • 29
    • 0020662181 scopus 로고
    • The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors
    • Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
    • (1983) Blood , vol.61 , pp. 36-40
    • Hilgartner, M.W.1    Knatterud, G.L.2
  • 30
    • 33846185403 scopus 로고    scopus 로고
    • A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
    • Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
    • (2007) Blood , vol.109 , pp. 546-551
    • Astermark, J.1    Donfield, S.M.2    DiMichele, D.M.3
  • 31
    • 33645573977 scopus 로고    scopus 로고
    • A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
    • Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
    • (2006) J Thromb Haemost , vol.4 , pp. 367-371
    • Santagostino, E.1    Mancuso, M.E.2    Rocino, A.3    Mancuso, G.4    Scaraggi, F.5    Mannucci, P.M.6
  • 32
    • 0038383602 scopus 로고    scopus 로고
    • Control of bleeding in patients with haemophilia A with inhibitors: a systematic review
    • Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
    • (2003) Haemophilia , vol.9 , pp. 464-520
    • Lloyd Jones, M.1    Wight, J.2    Paisley, S.3    Knight, C.4
  • 33
    • 13244262642 scopus 로고    scopus 로고
    • Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
    • Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
    • (2004) J Thromb Haemost , vol.2 , pp. 1700-1708
    • Aledort, L.M.1
  • 34
    • 30944461398 scopus 로고    scopus 로고
    • Thromboembolic adverse events after use of recombinant human coagulation factor VIIa
    • O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.
    • (2006) JAMA , vol.295 , pp. 293-298
    • O'Connell, K.A.1    Wood, J.J.2    Wise, R.P.3    Lozier, J.N.4    Braun, M.M.5
  • 35
    • 37749034295 scopus 로고    scopus 로고
    • Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues
    • Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14: 39-43.
    • (2008) Haemophilia , vol.14 , pp. 39-43
    • Aledort, L.M.1
  • 36
    • 30444433618 scopus 로고    scopus 로고
    • Therapeutic decision-making in inhibitor patients
    • Allen G, Aledort L. Therapeutic decision-making in inhibitor patients. Am J Hematol 2006; 81: 71-2.
    • (2006) Am J Hematol , vol.81 , pp. 71-72
    • Allen, G.1    Aledort, L.2
  • 37
    • 40349113432 scopus 로고    scopus 로고
    • Value added: increasing the power to assess treatment outcome in joint haemorrhages
    • Donfield SM, Astermark J, Lail AE, Gilbert SA, Berntorp E. Value added: increasing the power to assess treatment outcome in joint haemorrhages. Haemophilia 2008; 14: 276-80.
    • (2008) Haemophilia , vol.14 , pp. 276-280
    • Donfield, S.M.1    Astermark, J.2    Lail, A.E.3    Gilbert, S.A.4    Berntorp, E.5
  • 38
    • 40349085780 scopus 로고    scopus 로고
    • Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison
    • Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
    • (2008) Haemophilia , vol.14 , pp. 287-294
    • Young, G.1    Shafer, F.E.2    Rojas, P.3    Seremetis, S.4
  • 39
    • 18044380093 scopus 로고    scopus 로고
    • Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity
    • Watts RG. Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity. Am J Hematol 2005; 79: 58-60.
    • (2005) Am J Hematol , vol.79 , pp. 58-60
    • Watts, R.G.1
  • 40
    • 33750690191 scopus 로고    scopus 로고
    • Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography
    • Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemo-philia 2006; 12: 598-604.
    • (2006) Haemo-philia , vol.12 , pp. 598-604
    • Young, G.1    Blain, R.2    Nakagawa, P.3    Nugent, D.J.4
  • 41
    • 0002239144 scopus 로고    scopus 로고
    • Consensus development methods, and their use in clinical guideline development
    • 1-88.
    • Murphy MK, Black NA, Lamping DL et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998; 2: i-iv, 1-88.
    • (1998) Health Technol Assess , vol.2
    • Murphy, M.K.1    Black, N.A.2    Lamping, D.L.3
  • 42
    • 11044227414 scopus 로고    scopus 로고
    • Thrombin generation assay and other universal tests for monitoring haemophilia therapy
    • Varadi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004; 10(Suppl 2): 17-21.
    • (2004) Haemophilia , vol.10 , Issue.SUPPL 2 , pp. 17-21
    • Varadi, K.1    Turecek, P.L.2    Schwarz, H.P.3
  • 43
    • 50049135947 scopus 로고    scopus 로고
    • Thrombin generation testing in routine clinical practice: are we there yet?
    • van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008; 142: 889-903.
    • (2008) Br J Haematol , vol.142 , pp. 889-903
    • van Veen, J.J.1    Gatt, A.2    Makris, M.3
  • 44
    • 58149084459 scopus 로고    scopus 로고
    • Standardization and clinical utility of thrombin-generation assays
    • Berntorp E, Salvagno GL. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 2008; 34: 670-82.
    • (2008) Semin Thromb Hemost , vol.34 , pp. 670-682
    • Berntorp, E.1    Salvagno, G.L.2
  • 45
    • 34848862747 scopus 로고    scopus 로고
    • Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study
    • Dargaud Y, Luddington R, Gray E et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007; 139: 303-9.
    • (2007) Br J Haematol , vol.139 , pp. 303-309
    • Dargaud, Y.1    Luddington, R.2    Gray, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.